ConCallIQ
Go Pro
CAPLINPOINTLABORATORIES Diversified 15 May 2026

Caplin Point Laboratories Ltd — Q4 FY26

Caplin Point delivered a strong FY26 with revenue doubling over five years to ₹2,300 crore and liquid assets tripling to ₹2,726 crore.

bullish high
Compare with...
Revenue ₹600 Cr
EBITDA
PAT ₹173 Cr
EBITDA Margin
Duration 61 min
Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Receivable days increase

Receivable days rose to ~136 days (11 days due to forex revaluation), partly from a large El Salvador tender. Management expects normalization by Q2 FY27.

medium · analyst_question
R

Input cost inflation from tariffs

US tariffs on Chinese APIs and raw materials could increase COGS. Management noted highest impact product saw <2% COGS increase, but broader escalation remains a risk.

medium · analyst_question
R

Execution risk in capacity expansion

Large capex program (₹500 crore residual) and new injectable lines may face delays or regulatory hurdles, impacting growth timelines.

medium · data_observation